Table 2.
Donor and recipient CMV antibody status
| CMV status | Alemtuzumab | Conventional |
|---|---|---|
| Donor−/recipient− (%) | 20.5 | 22.6 |
| Donor−/recipient+ (%) | 25.2 | 25.9 |
| Donor+/recipient− (%) | 22.4 | 17.1 |
| Donor+/recipient+ (%) | 31.9 | 30.1 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.